Another HOT short term play here guys ASRT=FDA DECISION in 2 Weeks guys = 200%++ Potential ASRT-DD = Market Cap $102 Million -- Cash $76 Million --4 Marketed Products --Another Drug awating FDA approval (PDUFA DATE October 19) -- insider Bought shares at higher price = Could Jump 200-300% on FDA APPROVAL in 2 Weeks = STRONG BUY ..Link to presentation and Insider buying below .GLTA Marketcap $100 Million Cash: $76 Million Price $1.25 Presentation http://investor.assertiotx.com/static-files/d387e336-3ff2-45fb-b5de-1079e0c6dd94 Insider Buying http://openinsider.com/search?q=asrt
Guys better avoid this stock there is some manufacturing risk so FDA likely to reject the drug .I dont know if they resolved that issue but i think its better to avoid the stock but its your own decision .GL https://www.fool.com/earnings/call-...herapeutics-inc-asrt-q2-2019-earnings-ca.aspx With regard to our NDA filing for our long-acting cosyntropin for the diagnosis of adrenocortical insufficiency, our filing remains under active review, and we continue to move forward toward a scheduled PDUFA date of October 19. Our partner, West, the product supplier and IND holder, continues to investigate the manufacturing issue we discussed at our first-quarter earnings call. The significance of these manufacturing models remains unclear. However, if these manufacturing issues are not resolved in a timely manner, it is possible this could impact cosyntropin approval, or if approved, we may not be able to launch the products until these issues are resolved.
